Related Experiment Video
Updated: Nov 23, 2025

Live Cell Imaging to Assess the Dynamics of Metaphase Timing and Cell Fate Following Mitotic Spindle Perturbations
Published on: September 20, 2019
The ATM and ATR kinases regulate centrosome clustering and tumor recurrence by targeting KIFC1 phosphorylation
Guangjian Fan1, Lianhui Sun1, Ling Meng2
1Translational Medicine Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 201620, Shanghai, China.
Abstract:
Drug resistance and tumor recurrence are major challenges in cancer treatment. Cancer cells often display centrosome amplification. To maintain survival, cancer cells achieve bipolar division by clustering supernumerary centrosomes. Targeting centrosome clustering is therefore considered a promising therapeutic strategy. However, the regulatory mechanisms of centrosome clustering remain unclear. Here we report that KIFC1, a centrosome clustering regulator, is positively associated with tumor recurrence. Under DNA damaging treatments, the ATM and ATR kinases phosphorylate KIFC1 at Ser26 to selectively maintain the survival of cancer cells with amplified centrosomes via centrosome clustering, leading to drug resistance and tumor recurrence. Inhibition of KIFC1 phosphorylation represses centrosome clustering and tumor recurrence. This study identified KIFC1 as a prognostic tumor recurrence marker, and revealed that tumors can acquire therapeutic resistance and recurrence via triggering centrosome clustering under DNA damage stresses, suggesting that blocking KIFC1 phosphorylation may open a new vista for cancer therapy.
Insights
Centrosome amplification drives cancer recurrence and drug resistance. This study reveals KIFC1 phosphorylation by ATM/ATR kinases promotes survival of cancer cells with amplified centrosomes, suggesting KIFC1 inhibition as a therapeutic strategy.
Area of Science:
- Cell Biology
- Cancer Research
- Molecular Oncology
Background:
- Drug resistance and tumor recurrence are significant obstacles in cancer treatment.
- Cancer cells frequently exhibit centrosome amplification, a condition where cells possess more than two centrosomes.
- Centrosome clustering enables cancer cells with supernumerary centrosomes to undergo bipolar division, promoting survival and proliferation.
Purpose of the Study:
- To elucidate the regulatory mechanisms of centrosome clustering in cancer cells.
- To investigate the role of KIFC1 (kinesin family member C1) in centrosome clustering and its association with tumor recurrence.
- To explore the potential of targeting KIFC1 phosphorylation as a therapeutic strategy against drug-resistant cancers.
Main Methods:
- Investigated the association between KIFC1 expression and tumor recurrence.
- Examined the phosphorylation of KIFC1 at Ser26 by ATM and ATR kinases under DNA damaging conditions.
- Assessed the effect of KIFC1 phosphorylation inhibition on centrosome clustering, cancer cell survival, drug resistance, and tumor recurrence in preclinical models.
Main Results:
- KIFC1 was found to be positively associated with tumor recurrence in cancer.
- DNA damaging treatments induced ATM/ATR-mediated phosphorylation of KIFC1 at Ser26, which selectively promoted the survival of cancer cells with amplified centrosomes.
- Inhibition of KIFC1 phosphorylation effectively repressed centrosome clustering, leading to decreased drug resistance and tumor recurrence.
Conclusions:
- KIFC1 acts as a crucial regulator of centrosome clustering and is a prognostic marker for tumor recurrence.
- Cancer cells can acquire therapeutic resistance and recurrence by activating centrosome clustering under DNA damage stress.
- Targeting KIFC1 phosphorylation presents a promising new therapeutic avenue for overcoming drug resistance and preventing tumor recurrence in cancer patients.
Related Concept Videos
Destabilization of Microtubules
Intracellular Signaling Affects Focal Adhesions
Some...
Anaphase Promoting Complex
DNA Damage can Stall the Cell Cycle
Centrosome Duplication
To ensure that each daughter cell receives a centrosome after cell division, centrosome duplication...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

